Antiangiogenic therapy for patients with aggressive or refractory advanced non-small cell lung cancer in the second-line setting

作者：Reck Martin^*; Garassino Marina Chiara; Imbimbo Martina; Shepherd Frances A; Socinski Mark A; Shih Jin Yuan; Tsao Anne; Lee Pablo; Winfree Katherine B; Sashegyi Andreas; Cheng Rebecca; Varea Rocio; Levy Benjamin; Garon Edward

来源：Lung Cancer, 2018, 120: 62-69.

DOI：10.1016/j.lungcan.2018.03.025

• Angiogenesis
• Non-small-cell lung cancer
• Ramucirumab
• Nintedanib
• Immunotherapy

A majority of patients with advanced or metastatic non-small cell lung cancer (NSCLC) will experience disease progression after first-line therapy. Patients who have advanced NSCLC that is especially aggressive, which is defined as disease that rapidly progresses on first-line treatment or disease that is refractory to first-line treatment, have a critical unmet medical need. These patients have a poor prognosis in the second-line setting. Several studies have recently shown that treatment with an antiangiogenic therapy may benefit these patients. This review summarizes the approved antiangiogenic therapies for the treatment of patients with advanced NSCLC in the second-line setting, specifically focusing on the outcomes from subgroups of patients with rapidly progressing or refractory disease. Several antiangiogenic agents, as monotherapy or in combination with other treatments, have been or are currently being studied in patients with advanced NSCLC. Antiangiogenics that are approved for use in patients with advanced NSCLC are limited to bevacizumab in combination with chemotherapy (nonsquamous NSCLC), ramucirumab in combination with docetaxel (all histologies), and nintedanib in combination with docetaxel (adenocarcinoma histology). This review focuses on the efficacy, safety, and quality of life outcomes in the subpopulation of patients with rapidly progressing or refractory NSCLC treated with approved antiangiogenic therapies in the second-line setting. We also discuss the impact of newly approved immunotherapy agents on the outcomes of patients with aggressive or refractory disease. Studies in progress and planned future research will determine if combination treatment with antiangiogenics and immunotherapies will benefit patients with aggressive, advanced NSCLC.

• 出版日期2018-6